Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088166 · ClinicalTrials.gov registry record · Phase 3
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
A Phase 3 study, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00088166 is a Phase 3 study that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 200 participants.
The verdict
NCT00088166, a Phase 3 study, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.
Interventions
- DRUG hCRF
- DRUG placebo hCRF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088166
The ClinicalTrials.gov registry entry for NCT00088166 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celtic Pharma Development Services, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hCRF is the first listed.
NCT00088166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088166 about?
NCT00088166 is a clinical study titled "XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors". The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema). This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms.
What is the current status of trial NCT00088166?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2004-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00088166?
The interventions under investigation include: hCRF (DRUG), placebo hCRF (DRUG).
Who is sponsoring clinical trial NCT00088166?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.